Zealand Pharma A/S
OTC:ZLDPF

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
OTC:ZLDPF
Watchlist
Price: 100.51 USD 0.71% Market Closed
Market Cap: 7.1B USD
Have any thoughts about
Zealand Pharma A/S?
Write Note

Relative Value

The Relative Value of one ZLDPF stock under the Base Case scenario is 29.97 USD. Compared to the current market price of 100.51 USD, Zealand Pharma A/S is Overvalued by 70%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ZLDPF Relative Value
Base Case
29.97 USD
Overvaluation 70%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
0
vs Industry
12
Median 3Y
94.6
Median 5Y
74.1
Industry
7.6
Forward
267
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-12.9
Industry
22.1
Forward
-45.4
vs History
vs Industry
Median 3Y
-16.7
Median 5Y
-14.2
Industry
21.9
vs History
vs Industry
Median 3Y
-10.4
Median 5Y
-11.4
Industry
23.4
vs History
46
vs Industry
4
Median 3Y
9.6
Median 5Y
6.9
Industry
2.5
vs History
0
vs Industry
10
Median 3Y
90.3
Median 5Y
73.2
Industry
7.5
Forward
218.4
vs History
0
vs Industry
7
Median 3Y
62.6
Median 5Y
58.8
Industry
9.3
vs History
vs Industry
Median 3Y
-15.9
Median 5Y
-13.1
Industry
4.2
Forward
-48.1
vs History
vs Industry
Median 3Y
-13.6
Median 5Y
-12.5
Industry
4
Forward
-42.5
vs History
vs Industry
Median 3Y
-15.9
Median 5Y
-12.2
Industry
5.9
vs History
vs Industry
Median 3Y
-15.7
Median 5Y
-11.4
Industry
3.9
vs History
15
vs Industry
0
Median 3Y
52.2
Median 5Y
31.6
Industry
4.5

Multiples Across Competitors

ZLDPF Competitors Multiples
Zealand Pharma A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Zealand Pharma A/S
OTC:ZLDPF
44.5B USD 579.5 -42.3 -33.7 -32.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 043 586 -180 815.5 -219 567.6 -217 062.1
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 851.8 -472.5 -514.6 -500.9
AU
CSL Ltd
ASX:CSL
133.7B AUD 5.6 31.6 19.6 24.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
36.2B EUR 19.4 -136.1 -110 -80.1
P/S Multiple
Revenue Growth P/S to Growth
DK
Zealand Pharma A/S
OTC:ZLDPF
Average P/S: 3 458 735.4
579.5
497%
1.2
FR
Pharnext SCA
OTC:PNEXF
38 043 586
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 851.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.4
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
DK
Zealand Pharma A/S
OTC:ZLDPF
Average P/E: 211.6
Negative Multiple: -42.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 815.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.5 N/A N/A
AU
CSL Ltd
ASX:CSL
31.6
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -136.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
OTC:ZLDPF
Average EV/EBITDA: 16.2
Negative Multiple: -33.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 567.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.6 N/A N/A
AU
CSL Ltd
ASX:CSL
19.6
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -110 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Zealand Pharma A/S
OTC:ZLDPF
Average EV/EBIT: 21.2
Negative Multiple: -32.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 062.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.9 N/A N/A
AU
CSL Ltd
ASX:CSL
24.4
54%
0.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -80.1 N/A N/A

See Also

Discover More
Back to Top